Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation
ACS Medicinal Chemistry Letters2014Vol. 6(1), pp. 53–57
Citations Over TimeTop 10% of 2014 papers
Nicole C. Goodwin, Giovanni Cianchetta, Hugh A. Burgoon, Jason Healy, Ross Mabon, Eric D. Strobel, Jason Allen, Shuli Wang, Brian D. Hamman, David B. Rawlins
Abstract
The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of other kinases. Enzymatic kinetic studies showed these molecules to be noncompetitive with ATP, suggesting allosteric inhibition. X-ray crystallography confirmed that these sulfonamides are a rare example of a type III kinase inhibitor that binds away from the highly conserved hinge region and instead resides in the hydrophobic pocket formed in the DFG-out conformation of the kinase, thus accounting for the high level of selectivity observed.
Related Papers
- → Allosteric sites: remote control in regulation of protein activity(2015)144 cited
- → ASD v2.0: updated content and novel features focusing on allosteric regulation(2013)102 cited
- → Analysis of tractable allosteric sites in G protein-coupled receptors(2019)45 cited
- → Toward understanding the molecular basis for chemical allosteric modulator design(2012)39 cited
- → From Inducing Allosteric Signaling to Exploring the Allosteric Effect of SNPS and Allosteric Polymorphism(2020)1 cited